PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Treatment
What You Should Know: – PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing treatment regimens for patients taking semaglutide (commonly known by brand names Ozempic and Wegovy) and other widely used weight-management drugs. – Utilizing advanced artificial intelligence models, the report analyzes patient-specific genetic data to identify and quantify genetic […]
Body image concerns drive interest in GLP-1 weight loss drugs, study finds
A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.
Eli Lilly sues companies selling alternative versions of its weight loss drug : Shots – Health News – NPR
Eli Lilly sues companies selling alternative versions of its weight loss drug : Shots – Health News NPR Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs WIRED Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro CNBC Lilly sues four compounders over copies of weight-loss drugs Reuters Eli Lilly opens a new legal front […]
Lilly sues four compounders over copies of weight-loss drugs – Reuters
Lilly sues four compounders over copies of weight-loss drugs Reuters Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs WIRED Eli Lilly sues companies selling alternative versions of its weight loss drug : Shots – Health News NPR Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro CNBC Eli Lilly opens a new legal front […]
‘Ozempic Pills’ Are Just Around the Corner—And They’re Not From Ozempic’s Maker
The success of drugs such as Ozempic, Wegovy, and Zepbound has sparked a race among pharmaceutical labs worldwide. These medications are based on compounds originally developed for type 2 diabetes but have taken off as weight loss treatments. Orforglipron. U.S. drugmaker Eli Lilly announced that its new treatment, orforglipron, has completed the third phase of […]
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Related Stocks: NAS:LEXX, NAS:LEXXW,
Eli Lilly is stepping up its fight against copycat weight loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. Read more…
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that’s already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound’s prospects still look bright, but some recent developments point […]
Incretin-based Drugs Market Forecast Report 2025-2034 Featuring AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, GSK, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, Viatris – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering. The Incretin-based Drugs Market was valued at USD 37.4 billion in 2024, and is projected to reach USD 68.7 billion by 2034, rising at a CAGR of 6.3%. The market is categorized by drug […]
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs – WIRED
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs WIRED Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro CNBC Lilly sues four compounders over copies of weight-loss drugs Reuters Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs Houston Public Media Eli Lilly opens a new legal front in its battle […]